Omega-3 fatty acid ( DrugBank: Omega-3, Omega-3 fatty acid )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	3
66	IgA nephropathy	2

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04586933 (ClinicalTrials.gov)	December 10, 2020	22/9/2020	Nutrition in Rheumatic Diseases	Nutritional Intervention in Rheumatic Diseases: Effect of Marine Omega-3 Fatty Acids and Individual Dietary Guidance	Spondyloarthritis;Rheumatoid Arthritis;Polyarthritis	Dietary Supplement: Omega-3;Dietary Supplement: Placebo (soya);Behavioral: Dietary guidance	Haukeland University Hospital	GC Rieber Oils AS	Recruiting	18 Years	75 Years	All	120	N/A	Norway
2	NCT01618019 (ClinicalTrials.gov)	November 2010	8/6/2012	N-3 PUFA and Rheumatoid Arthritis in Korea	Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Omega-3 fatty acid;Dietary Supplement: Placebo	Hanyang University	NULL	Completed	18 Years	80 Years	All	109	N/A	Korea, Republic of
3	NCT00399282 (ClinicalTrials.gov)	October 2006	13/11/2006	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis	Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omega-3 and Vitamin E supplementation	Shahid Beheshti Medical University	NULL	Completed	16 Years	75 Years	Both	75	Phase 1	Iran, Islamic Republic of

66. IgA nephropathy

---

Clinical trials : 255 /  Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00498368 (ClinicalTrials.gov)	February 2009	9/7/2007	Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy	A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy	IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement	Mayo Clinic	Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen	Completed	18 Years	70 Years	All	34	Phase 4	United States
2	NCT00549692 (ClinicalTrials.gov)	November 2007	25/10/2007	Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy	Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy	IgA Nephropathy	Drug: Omega-3 fatty acid ethylester90	Kuhnil Pharmaceutical Co., Ltd.	Pronova BioPharma ASA	Completed	18 Years	N/A	Both	152	Phase 3	Korea, Republic of

Back to top